Solving Debilitating Genetic Diseases
Code Bio, headquartered in Greater Philadelphia, was founded by McVeigh as well as entrepreneurs Robert C. Getts and Lori A. Getts. The biotech business seeks to provide a novel, potentially re-dosable gene delivery platform to patients in an effort to cure debilitating genetic diseases.
3DNA, the proprietary synthetic vector designed by the company, has the potential to combat several different genetic disorders, including Duchenne Muscular Dystrophy (DMD) and Type 1 Diabetes. The DNA-based vector from Code Bio is capable of delivering genes both large and small and utilizes a dual-targeting strategy to prevent unintended protein bindings and minimize off-target toxicities. According to the startup company, the vector is easily produced in bulk and stored.
“At 4BIO we have always been dedicated to delivering lasting, curative treatments for chronic diseases through the use of advanced therapies,” said Dr. Kuzmin. “...I believe this is something the team at Code Bio has the ability to achieve. We are delighted to have supported the company throughout its start-up and business planning process and look forward to working closely with the team as they progress Code Bio’s novel pipeline of gene therapies.”
The startup biotech business is currently seeking out strategic partnerships to build out further programs for various genetic diseases.
Gene Therapy Industry Projections
Code Biotherapeutics is attempting to solve issues of complex manufacturing, delivery limitations, and re-dosability in the expanding gene therapy industry. Market research expects the global gene therapy market to reach $25.67 billion by 2027 at a CAGR of 33.6%. Code Biotherapeutics joins other startup companies in the industry, like Elevate Bio, in the pursuit of effective and scalable gene therapy treatments.
About the Author
James White is a Michigan State University graduate with a BS in Environmental Biology. He is interested in reporting emerging trends in technology, especially with regard to alternative energy and environmental conservation.